Scholar Rock (SRRK) to Release Earnings on Friday

Scholar Rock (NASDAQ:SRRK) will likely be announcing its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $0.05 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 14, 2025 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.32). During the same quarter in the previous year, the company earned ($0.60) EPS. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Price Performance

Shares of Scholar Rock stock opened at $28.80 on Friday. The stock’s fifty day moving average is $32.63 and its 200 day moving average is $33.43. Scholar Rock has a one year low of $22.71 and a one year high of $46.98. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33. The stock has a market cap of $2.77 billion, a P/E ratio of -9.90 and a beta of 0.79.

Insider Activity

In other Scholar Rock news, Director Srinivas Akkaraju bought 113,025 shares of the firm’s stock in a transaction dated Monday, October 6th. The stock was acquired at an average price of $38.65 per share, for a total transaction of $4,368,416.25. Following the completion of the purchase, the director owned 500,439 shares of the company’s stock, valued at approximately $19,341,967.35. This represents a 29.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total transaction of $32,725.18. Following the completion of the sale, the director owned 33,914 shares of the company’s stock, valued at approximately $1,103,222.42. The trade was a 2.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 7,537 shares of company stock valued at $242,088. 13.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Several large investors have recently added to or reduced their stakes in SRRK. Balyasny Asset Management L.P. acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $33,062,000. Bank of America Corp DE increased its stake in shares of Scholar Rock by 97.4% in the second quarter. Bank of America Corp DE now owns 644,232 shares of the company’s stock worth $22,819,000 after buying an additional 317,847 shares during the last quarter. Vestal Point Capital LP increased its position in shares of Scholar Rock by 15.4% in the 2nd quarter. Vestal Point Capital LP now owns 1,500,000 shares of the company’s stock worth $53,130,000 after purchasing an additional 200,000 shares during the last quarter. Raymond James Financial Inc. increased its holdings in Scholar Rock by 104.4% in the second quarter. Raymond James Financial Inc. now owns 125,477 shares of the company’s stock valued at $4,444,000 after buying an additional 64,098 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Scholar Rock by 37.4% in the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after acquiring an additional 54,555 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on SRRK. Cantor Fitzgerald started coverage on shares of Scholar Rock in a research note on Thursday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Wednesday, October 8th. Truist Financial lowered their price objective on Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, October 20th. Piper Sandler cut their target price on Scholar Rock from $52.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, September 24th. Finally, Leerink Partnrs upgraded Scholar Rock to a “strong-buy” rating in a research note on Monday, September 15th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $48.50.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.